tiprankstipranks
Trending News
More News >
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H (HK:2252)
:2252
Hong Kong Market

Shanghai MicroPort MedBot (Group) Co., Ltd. Class H (2252) AI Stock Analysis

Compare
2 Followers

Top Page

HK

Shanghai MicroPort MedBot (Group) Co., Ltd. Class H

(2252)

Rating:44Neutral
Price Target:
The overall score reflects strong revenue growth and potential long-term support suggested by technical analysis but is weighed down by significant financial challenges, such as negative profitability and cash flow, and high leverage. The valuation score is also low due to the negative P/E ratio and lack of dividends, indicating caution for investors.

Shanghai MicroPort MedBot (Group) Co., Ltd. Class H (2252) vs. iShares MSCI Hong Kong ETF (EWH)

Shanghai MicroPort MedBot (Group) Co., Ltd. Class H Business Overview & Revenue Model

Company DescriptionShanghai Microport Medbot (Group) Co., Ltd. engages in the research and development, design, manufacture, and sale of surgical robots in the People's Republic of China and Europe. It offers Toumai, a laparoscopic surgical robot for use in urologic, gynecologic, thoracic, and general surgeries; DFVision, a 3D electronic laparoscope, which is used in laparoscopic surgeries for abdominal, thoracic, and pelvic organs; Honghu, an orthopedic surgical robot for knee arthroplasty and hip arthroplasty; R-One, a vascular interventional surgical robot for coronary angioplasty; and iSR'obot, a Mona Lisa robotic transperineal prostate biopsy system. The company also provides spine surgical robots; trans-bronchial surgical robots for trans-bronchial diagnosis and treatment; TAVR surgical robots for heart valve replacement surgery; and automated needle targeting robotics systems for percutaneous lung biopsy and percutaneous nephrolithotomy. Shanghai Microport Medbot (Group) Co., Ltd. was founded in 2014 and is based in Shanghai, China. Shanghai Microport Medbot (Group) Co., Ltd. operates as a subsidiary of MicroPort Scientific Corporation.
How the Company Makes MoneyShanghai MicroPort MedBot generates revenue primarily through the sale and lease of its robotic-assisted surgical systems to healthcare providers. The company also earns income from providing maintenance services and selling consumables and accessories associated with its robotic systems. Additionally, strategic partnerships with medical institutions and ongoing research and development initiatives contribute to its financial growth by fostering innovation and expanding its market presence.

Shanghai MicroPort MedBot (Group) Co., Ltd. Class H Financial Statement Overview

Summary
Shanghai MicroPort MedBot demonstrates impressive revenue growth but faces significant challenges in achieving profitability and managing its cash flow effectively. The high leverage and negative cash flow are potential risks that need to be managed to ensure long-term financial stability. Continued focus on improving operational efficiency and reducing costs will be critical.
Income Statement
40
Negative
The company has shown significant revenue growth over the past few years, with Total Revenue increasing from 2.15 million in 2021 to 257.25 million in 2024. However, profitability remains a concern with negative Net Income and high negative EBIT and EBITDA margins, indicating operational inefficiencies and high costs relative to revenue.
Balance Sheet
50
Neutral
The company's Debt-to-Equity ratio is moderately high, reflecting a high level of leverage which could be risky if not managed properly. The Equity Ratio has been decreasing, indicating a declining proportion of equity financing. Return on Equity is negative due to net losses, suggesting challenges in generating returns for shareholders.
Cash Flow
30
Negative
The company struggles with negative Free Cash Flow and Operating Cash Flow, which raises concerns about its ability to generate cash internally. The lack of positive cash flow from operations could limit growth and investment opportunities unless addressed.
Breakdown
Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
257.25M104.59M21.60M2.15M0.00
Gross Profit
86.22M14.69M6.56M919.00K0.00
EBIT
-488.75M-975.14M-1.10B-610.18M-158.43M
EBITDA
-413.34M-893.36M-1.01B-543.84M-160.93M
Net Income Common Stockholders
-642.41M-1.01B-1.17B-542.69M-261.25M
Balance SheetCash, Cash Equivalents and Short-Term Investments
612.23M507.71M747.96M1.94B1.50B
Total Assets
1.28B1.43B1.93B2.79B1.70B
Total Debt
691.33M560.42M219.95M204.68M18.88M
Net Debt
79.10M52.71M-528.01M-1.74B-1.48B
Total Liabilities
1.02B926.15M522.25M401.73M262.90M
Stockholders Equity
278.20M519.48M1.42B2.39B1.44B
Cash FlowFree Cash Flow
0.00-634.30M-1.09B-674.47M-118.05M
Operating Cash Flow
0.00-567.84M-898.48M-540.49M-103.04M
Investing Cash Flow
0.00-58.38M-267.82M-396.57M-15.01M
Financing Cash Flow
0.00385.68M-27.95M1.39B1.56B

Shanghai MicroPort MedBot (Group) Co., Ltd. Class H Technical Analysis

Technical Analysis Sentiment
Positive
Last Price17.24
Price Trends
50DMA
16.64
Positive
100DMA
17.27
Positive
200DMA
13.09
Positive
Market Momentum
MACD
<0.01
Negative
RSI
61.73
Neutral
STOCH
81.77
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2252, the sentiment is Positive. The current price of 17.24 is above the 20-day moving average (MA) of 15.94, above the 50-day MA of 16.64, and above the 200-day MA of 13.09, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 61.73 is Neutral, neither overbought nor oversold. The STOCH value of 81.77 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2252.

Shanghai MicroPort MedBot (Group) Co., Ltd. Class H Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
54
Neutral
$5.38B3.40-45.06%3.28%16.75%-0.02%
44
Neutral
HK$17.55B-160.49%141.72%38.39%
$8.87B12.846.22%1.96%
$13.76B26.068.17%
$2.67B11.706.68%4.72%
59
Neutral
HK$3.85B21.454.47%-9.75%
55
Neutral
HK$86.48B-8.98%-54.66%-123.11%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:2252
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H
17.24
4.88
39.48%
SFOSF
Shanghai Fosun Pharmaceutical (Group) Co
1.96
0.22
12.64%
WXIBF
Wuxi Biologics (Cayman)
2.96
1.26
74.12%
YZOFF
Yangtze Optical Fibre and Cable Joint Stock Co
1.64
0.62
60.78%
HK:9926
Akeso, Inc.
95.45
55.35
138.03%
HK:1873
Viva Biotech Holdings
1.81
1.20
196.72%

Shanghai MicroPort MedBot (Group) Co., Ltd. Class H Corporate Events

Shanghai MicroPort MedBot Announces Director Resignation and Audit Committee Restructuring
Apr 30, 2025

Shanghai MicroPort MedBot (Group) Co., Ltd. announced the resignation of Mr. Chen Xinxing as a non-executive director and audit committee member, effective April 30, 2025, as he intends to focus on other work commitments. The board expressed gratitude for his contributions and confirmed no disagreements with the board. Following his departure, the audit committee will be restructured to include Mr. Chung Wai Man, Dr. Li Minghua, and Mr. Yao Haisong, with Mr. Chung continuing as chairperson.

Shanghai MicroPort MedBot Announces Board Composition and Roles
Apr 30, 2025

Shanghai MicroPort MedBot (Group) Co., Ltd. has announced the composition of its board of directors, highlighting the roles and functions of each member. This announcement is significant as it outlines the leadership structure and strategic direction of the company, which could influence its operations and market positioning within the medical technology industry.

Shanghai MicroPort MedBot’s Toumai Remote Gains Landmark Approval for Global Remote Surgery
Apr 23, 2025

Shanghai MicroPort MedBot has achieved a significant milestone with the approval of its Toumai Remote laparoscopic surgical robot by the National Medical Products Administration of China. This approval marks the world’s first for full-department application in remote surgery, enhancing the company’s product portfolio and positioning it as a leader in the global remote surgery field. The Toumai Remote system, compatible with multiple communication networks, has been instrumental in performing nearly 400 remote surgeries across various countries, showcasing its innovative capabilities and establishing numerous national and world records.

Shanghai MicroPort MedBot Proposes Board Expansion and New Executive Director
Mar 27, 2025

Shanghai MicroPort MedBot (Group) Co., Ltd. has proposed an amendment to its Articles of Association to increase the number of board seats from eight to nine, which will be considered at the upcoming annual general meeting. Additionally, the company has nominated Mr. Liu Yu as an executive director, pending shareholder approval. Mr. Liu brings over 30 years of experience in the pharmaceuticals and medical devices industry, having held significant roles in various companies, which could enhance the company’s strategic direction and operational efficiency.

Shanghai MicroPort MedBot Reports Significant Revenue Growth and Reduced Losses for 2024
Mar 27, 2025

Shanghai MicroPort MedBot reported a significant revenue increase of 146% for the year ended December 31, 2024, reaching RMB257.2 million, driven by strong sales growth in domestic and overseas markets. Despite a net loss of RMB647.1 million, the company improved its financial performance by reducing its net loss by 36.8% compared to the previous year, attributed to increased gross profit, reduced R&D costs, and decreased administrative expenses. The company also successfully reduced its net free cash outflow by 42%, reflecting strategic focus and efficiency measures, although these gains were partially offset by an impairment loss on an overseas investment.

Shanghai MicroPort MedBot Announces Upcoming Board Meeting for Year-End Results
Mar 17, 2025

Shanghai MicroPort MedBot (Group) Co., Ltd. has announced that its board of directors will hold a meeting on March 27, 2025, to discuss and approve the final results for the year ending December 31, 2024. The meeting will also consider the recommendation of a final dividend and address other business matters, which could impact the company’s financial strategy and shareholder returns.

Shanghai MicroPort MedBot Projects Significant Revenue Growth Amidst Reduced Losses
Mar 3, 2025

Shanghai MicroPort MedBot (Group) Co., Ltd. has announced an expected revenue growth of 145% to 155% for the year ending December 31, 2024, driven by strong sales in both domestic and international markets. Despite this growth, the company anticipates an adjusted net loss of RMB435 million to RMB521 million, a significant reduction from the previous year’s loss, due to increased revenue and decreased operating expenses.

Shanghai MicroPort MedBot’s Surgical Robot Gains Regulatory Approval
Feb 11, 2025

Shanghai MicroPort MedBot has received approval from the National Medical Products Administration of China for its Toumai Single-arm and Single-port Laparoscopic Surgical Robot. This approval marks a significant milestone in the company’s business development, enhancing its product portfolio and market competitiveness. The Toumai Single-arm robot, characterized by its unique single-arm structure and sophisticated design, offers clinical advantages such as smaller wounds and less pain, thus improving post-operative aesthetics. This development is expected to strengthen the company’s position in both the domestic and international markets.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.